| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
a The Boca Raton Comprehensive Cancer Center, Boca Raton, Florida, USA; b Washington University School of Medicine, St. Louis, Missouri, USA; c Boston Baskin Cancer Group, Memphis, Tennessee, USA; d The Alta Bates Comprehensive Cancer Center, Berkeley, California, USA; e New York University School of Medicine, New York, New York, USA; f The St. Vincent’s Comprehensive Cancer Center, New York, New York, USA; g Michigan Cancer Specialists, Roseville, Michigan, USA
Correspondence: Mohammad Jahanzeb, M.D., Chief, Division of Hematology/Oncology, University of Tennessee College of Medicine, 1331 Union Ave., Suite 800, Memphis, Tennessee 38104, USA. Telephone: 901-255-3132; Fax: 901-255-3134; e-mail: mjahanze{at}utmem.edu
Purpose. Human epidermal growth factor receptor 2 (HER2) overexpression is associated with a more aggressive form of breast cancer that responds well to trastuzumab therapy. Trastuzumab-based combination regimens have shown greater antitumor activity than chemotherapy alone. These findings, coupled with the favorable antitumor activity and tolerability profile of vinorelbine in breast cancer, provided the rationale for investigating the novel combination of vinorelbine and trastuzumab.
Patients and Methods. A phase II, open-label trial of intravenous vinorelbine (30 mg/m2 on day 1, then weekly) and trastuzumab (4 mg/kg on day 0, then 2 mg/kg weekly) was conducted in previously untreated HER2+ metastatic breast cancer patients. Vinorelbine dose was adjusted for grade 3/4 neutropenia; patients remained on combination therapy until disease progression or patient withdrawal due to adverse events.
Results. Of 40 enrolled patients (median age 51 years, range 30-82), 37 were evaluable for response. Overall response rate was 78% (29/37, 95% confidence interval [CI] 62%-90%), including four (11%, 95% CI 3%-25%) complete and 25 (68%) partial responses. Objective tumor response correlated with degree of HER2 positivity: immunohistochemistry (IHC) 3+ = 82% (18/22) response and IHC 2+ = 58% (7/12) response. Median time to progression was 72 weeks (95% CI 37-138 weeks); median survival has not been reached. Grade 3/4 neutropenia was the most frequent serious toxicity and cause of dose reductions (9% of courses) and omissions (10% of courses). No patient experienced serious cardiac toxicity.
Conclusions. Weekly vinorelbine/trastuzumab offers a high therapeutic index as initial therapy in patients with HER2+ metastatic breast cancer. Further investigation of this novel regimen is planned.
This article has been cited by other articles:
 |
|
 |
|
  S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, et al. Third consensus on medical treatment of metastatic breast cancer Ann. Onc., November 1, 2009; 20(11): 1771 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chan and R. de Boer Use of Trastuzumab for Metastatic Breast Cancer in Australia: Inaccurate Results and Alternative Interpretation of Findings J. Clin. Oncol., December 10, 2007; 25(35): 5662 - 5663. [Full Text] [PDF]
|
|
|
|
|
|
C. Catania, M. Medici, E. Magni, E. Munzone, D. Cardinale, L. Adamoli, G. Sanna, I. Minchella, D. Radice, A. Goldhirsch, et al. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination Ann. Onc., December 1, 2007; 18(12): 1969 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Hudis Trastuzumab -- Mechanism of Action and Use in Clinical Practice N. Engl. J. Med., July 5, 2007; 357(1): 39 - 51. [Full Text] [PDF]
|
|
|
|
|
|
A Chan A review of the use of trastuzumab (Herceptin(R)) plus vinorelbine in metastatic breast cancer Ann. Onc., July 1, 2007; 18(7): 1152 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Limentani, A. M. Brufsky, J. K. Erban, M. Jahanzeb, and D. Lewis Phase II Study of Neoadjuvant Docetaxel, Vinorelbine, and Trastuzumab Followed by Surgery and Adjuvant Doxorubicin Plus Cyclophosphamide in Women With Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancer J. Clin. Oncol., April 1, 2007; 25(10): 1232 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer Oncologist, March 1, 2007; 12(3): 253 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. N. Harris, F. You, S. J. Schnitt, A. Witkiewicz, X. Lu, D. Sgroi, P. D. Ryan, S. E. Come, H. J. Burstein, B.-A. Lesnikoski, et al. Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1198 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Beslija, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, V Heinemann, J Jassem, W. Kostler, M Krainer, et al. Second consensus on medical treatment of metastatic breast cancer Ann. Onc., February 1, 2007; 18(2): 215 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jackisch HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy Oncologist, September 1, 2006; 11(suppl_1): 34 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Papaldo, A. Fabi, G. Ferretti, M. Mottolese, A. M. Cianciulli, B. Di Cocco, M. S. Pino, P. Carlini, S. Di Cosimo, I. Sacchi, et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease Ann. Onc., April 1, 2006; 17(4): 630 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, S. Chan, D. Grimes, A. Anton, A. Lluch, et al. Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group J. Clin. Oncol., July 1, 2005; 23(19): 4265 - 4274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Toi, T. Saeki, K. Aogi, M. Sano, K. Hatake, T. Asaga, Y. Tokuda, S. Mitsuyama, M. Kimura, T. Kobayashi, et al. Late Phase II Clinical Study of Vinorelbine Monotherapy in Advanced or Recurrent Breast Cancer Previously Treated with Anthracyclines and Taxanes Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 310 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hamilton and G. Hortobagyi Chemotherapy: What Progress in the Last 5 Years? J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775. [Full Text] [PDF]
|
|
|
|
|
|
C. Bernard-Marty, F. Cardoso, and M. J. Piccart Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer Oncologist, November 1, 2004; 9(6): 617 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Leyland-Jones, K. Gelmon, J.-P. Ayoub, A. Arnold, S. Verma, R. Dias, and P. Ghahramani Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel J. Clin. Oncol., November 1, 2003; 21(21): 3965 - 3971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Burstein, L. N. Harris, P. K. Marcom, R. Lambert-Falls, K. Havlin, B. Overmoyer, R. J. Friedlander Jr., J. Gargiulo, R. Strenger, C. L. Vogel, et al. Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm J. Clin. Oncol., August 1, 2003; 21(15): 2889 - 2895. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
